CN
Newsroom


A Customer-centric, Innovative
and Reliable CDMO with Global Solutions

1 of 5 result

Small MoleculesApr 27, 2025

Comprehensive Analytical R&D and QC Expertise in Pharmaceutical Development

This white paper details our extensive capabilities in Analytical Research and Development (R&D) and Quality Control (QC) for pharmaceutical drug development. It highlights our expertise in method development, structure elucidation, and method troubling. Our goal is to ensure the highest standards of quality and efficiency in drug development and manufacturing.

Small MoleculesMar 13, 2025

Facilitating PROTAC Drugs Development with Innovative Processes

The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.

Small MoleculesJan 06, 2025

Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost

Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost

Small MoleculesNov 25, 2024

Co-processing: Co-Precipitation Technology (CPT) for the Enhancement of Flowability and Bulk Density

Formulating compressed tablets is one of the most widely used oral solid form dosages. However, a vital first step is choosing a suitable manufacturing approach and the right excipients to support the desired therapeutic effect.

ENT-03 GRC Poster

Small MoleculesNov 09, 2024

ENT-03 GRC Poster

ENT-03 was predicted to be the mammalian equivalent of trodusquemine, based on knowledge of the bile acids produced in mammals, such as 7-HOCA. The individual C-25 isomers of ENT-03 were prepared and both detected in mouse brain. Trodusquemine and ENT-03 have both demonstrated dramatic effects in obesity and insulin resistance. (25S)-ENT-03 was selected for development for the treatment of diabetes and obesity.

Become part of Porton' s community to access personalized insights and resources.
Subscribe To Our Mailing List
Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review our Legal Disclaimer Terms and Porton Privacy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200